Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond - Wikidata - wikimedia - TriplyDB

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

http://www.wikidata.org/entity/Q27826351

about

Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles Muddled mechanisms: recent progress towards antimalarial target identification An open source pharma roadmap Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum The Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic Screens Esterase mutation is a mechanism of resistance to antimalarial compounds Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening Developing transmission-blocking strategies for malaria control.Reliance of Wolbachia on High Rates of Host Proteolysis Revealed by a Genome-Wide RNAi Screen of Drosophila Cells.Discovery of a Novel Antifungal Agent in the Pathogen Box.Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways.Herbicidal properties of antimalarial drugs.The need to compare: assessing the level of agreement of three high-throughput assays against Plasmodium falciparum mature gametocytes.Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.The Candidate Antimalarial Drug MMV665909 Causes Oxygen-Dependent mRNA Mistranslation and Synergizes with Quinoline-Derived Antimalarials.Modulation of Antimalarial Activity at a Putative Bisquinoline Receptor In Vivo Using Fluorinated Bisquinolines.A validated bioluminescence-based assay for the rapid determination of the initial rate of kill for discovery antimalarials.Antimalarial activity of Malaria Box Compounds against Plasmodium falciparum clinical isolates.Biological Studies and Target Engagement of the 2-C-Methyl-d-Erythritol 4-Phosphate Cytidylyltransferase (IspD)-Targeting Antimalarial Agent (1R,3S)-MMV008138 and Analogs.malERA: An updated research agenda for basic science and enabling technologies in malaria elimination and eradication.An automated high-throughput system for phenotypic screening of chemical libraries on C. elegans and parasitic nematodes.Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model.Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii.Exploiting the Evolutionary Relationship between Malarial Parasites and Plants To Develop New Herbicides.Recent buzz in malaria research.Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box.Specific Inhibition of the Bifunctional Farnesyl/Geranylgeranyl Diphosphate Synthase in Malaria Parasites via a New Small-Molecule Binding Site.A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open Access Malaria Box.Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules.Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry.Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.Novel Antifungal Compounds Discovered in Medicines for Malaria Venture's Malaria Box.Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni.Diverse antimalarials from whole-cell phenotypic screens disrupt malaria parasite ion and volume homeostasis.Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and a Current Screening Methodologies in Drug Discovery for Selected Human Diseases Repurposing of an old drug: In vitro and in vivo efficacies of buparvaquone against Echinococcus multilocularis Recent Breakthroughs and Ongoing Limitations in Research Screening for potential prophylactics targeting sporozoite motility through the skin

P2860

Q26883657-8C0E1C0F-E20C-429C-831F-EE3AD0620A9C Q28066421-0922A723-BC24-450A-8570-587AA2DD7BA6 Q29475096-5CE09F5E-8F73-41AE-9EB8-0CBBF14AD0AA Q30041617-8DD3FE88-55C8-43F8-B106-CD313A9EE5D3 Q30042965-93DF44BD-D791-4EB9-8C0C-D57AF809EA8F Q30043987-49D418C1-78A7-471F-A2EE-277114A2AA1F Q33560788-329DD187-9234-4CE6-AE51-B6F4291B5374 Q33880789-29CCBACF-183C-4A49-9B6D-C9E028E15132 Q36270484-06C2BFB0-6CE5-486C-8195-14B7B6FDAA20 Q36354735-E7BED0F3-86DE-4B89-BC21-3A8AB73FE50C Q37358648-62E42ADC-606B-4012-A91A-B067D201076E Q37731378-6B77DABB-1CDE-4FFB-91B5-1E3F0BE98EE6 Q37737884-32630BE3-F9B3-4648-B1AD-7C7E36EA4855 Q38695331-CE7F10E7-C04D-49AB-ADCE-2F39CB2F6BFC Q38708103-2E02004C-E565-42BC-89A7-50ACD62C4B92 Q38750426-A011B4C1-DB2D-4DFD-B2EB-ED0C4F08AF57 Q38780035-DBEFFD18-8918-46A0-A007-03B78F6D563D Q43434845-80765B23-9B84-40D7-80DE-53C71696718B Q45071037-891A01AF-9BCC-4E35-90F3-C0ED4866828A Q47162062-A56969E6-BECB-4F7F-BDBF-2758C3BFDD15 Q47177309-22B33B60-4E4F-4605-912D-D98E9905CA9B Q47198396-4D92454A-3099-4CD1-8F1F-B95333D3A622 Q47381598-96C63637-0714-4BBB-9655-B5084F8252DB Q47998477-89FCA956-0BC3-4535-8925-567D65FB5449 Q48003976-0A8B9A02-AD3F-4E14-8C33-DAF26E9440E0 Q48016385-B756F1DF-D100-4C8D-ABF4-84D68EC87591 Q48020178-10661434-FCA8-4B4F-B36D-59B28D5CB5A6 Q48022259-078DD39F-1231-45F0-99CB-883C97BAD691 Q48022900-ADBDF78C-0E89-4105-A8F5-E9367C87B161 Q50047043-DA624A39-8914-449C-B192-B2F111EFCA17 Q52574425-E6AC784F-58C0-46D8-B465-0D9A50B671FE Q52725067-DD6E95FC-026D-4432-A1A4-D0ED7BD0AC20 Q55008133-9C44E3DE-3CC1-462E-9A5C-53F4096892B3 Q55334152-B377194B-A1A2-4A0C-9933-15E61ECF5368 Q56344152-A7C90AA7-2C80-466A-8BFB-7C104478D9CF Q56383714-6366F1AF-011A-4B75-93FF-C1346195E21C Q57169512-1A5DA73C-EE07-4C7C-9092-ECC94DFFC502 Q58584921-08A2FC11-5CF8-4780-9BAF-21B2C7CCC0A1 Q58767983-39171BB1-5110-4E10-B6D2-5C0692C86B93 Q58781866-70E733D4-1A42-4B5E-B71C-CB16D65BA2AF

P2860

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

http://www.wikidata.org/entity/Q27826351

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@ast

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@en

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@nl

type

label

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@ast

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@en

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@nl

prefLabel

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@ast

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@en

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@nl

P1433

Q27826351-9A669212-315C-4A78-BDC9-E97985FD29FD

P1476

Q27826351-745C8089-D181-405F-B057-EA1075DAC2B7

P2093

Q27826351-01016F0C-5D49-4E6E-86EA-3788985BBF33

Q27826351-02D80E0E-B29B-4BB7-ACCE-40F1EB19252B

Q27826351-02F1F2CE-8193-4DE9-BDD1-219526D069CA

Q27826351-036FB44D-845A-4C24-A506-9780F21B70D2

Q27826351-044ADD10-C5FE-44CD-ACF6-BE979392E53A

Q27826351-0656FDB6-C9AB-4353-9C1F-C16CA8F3AF60

Q27826351-06E96F6B-4B9B-4B55-91C9-6F34FB97BAED

Q27826351-0AA8B11D-4F41-4FAA-A354-34420AF10221

Q27826351-0DFF1781-0F3F-4CC1-907C-6003A50CA7E8

Q27826351-0E7E6370-AE3F-4A79-9CBE-4F3CE17CD434

P2860

Q27826351-0238FB1A-7406-49C2-84B5-43C79DC94A1D

Q27826351-0C0B297E-1A48-40D6-9D48-DC060F4595AD

Q27826351-0D79C645-4648-4E68-A526-3570F6B7FB78

Q27826351-0DCCFC63-4108-4F3C-B306-CD9398D628D7

Q27826351-0EEC1C0A-E618-4A69-B296-E8961FB60F5F

Q27826351-110A6220-96FD-46A5-A63D-8B4DC063AAB2

Q27826351-1BA4C44F-EFC8-4043-B33F-BD15C8078914

Q27826351-27C8699D-51DA-4521-B660-BDCCBDEE77C9

Q27826351-281AB30F-CA06-4662-9825-05A09B9395BA

Q27826351-33950DEF-8CA6-4A03-B234-8509F8EE8D77

P304

Q27826351-2B236A47-50FD-42CD-86A6-054F500B64F8

P31

Q27826351-1ABAF48F-8912-499B-80D8-F5188F93750C

P3181

Q27826351-5CE4A2FC-A163-420F-8C77-6BD8930F9C88

P356

Q27826351-B5231EEC-51D0-4EDC-AF6A-09821DF28A2A

P407

Q27826351-BB64BCDE-B8B3-4D7C-A7CC-DA6BA22F73B3

P433

Q27826351-C6BD78F3-9245-47FC-AFBB-A20442452530

P478

Q27826351-9B6A401C-0ED2-4037-A20F-F389B3918F40

P50

Q27826351-01295560-8CAC-4B2E-B4CE-1C692FCC9A3B

Q27826351-0F621A0D-E228-489C-99A4-7BF6C23DC916

Q27826351-158FEC35-538B-43D4-8AEB-B48066ED3AEE

Q27826351-1A879681-3E91-43DB-BDA2-387D8A09CF31

Q27826351-1A8E2E52-AFCA-44D3-8B24-4BB328403C2C

Q27826351-1CB677A5-CD4D-47D5-A1FA-B937E78AF093

Q27826351-22E29A70-DC46-4E75-A0B2-DD61DEABE354

Q27826351-24FB6311-58E1-42F3-ADC2-C3272D259B0F

Q27826351-26A6291F-5DFD-4AC7-B9A4-0A6ACBF7C07B

Q27826351-2F750AD4-8523-40CB-8918-2D6C1C2A8F49

P577

Q27826351-A245294C-AEF3-48D1-8A29-2125B791BB47

P698

Q27826351-4527B6BA-066F-4367-9C54-FCB731B6A2D8

P921

Q27826351-6DA5B8BC-91D8-4797-8699-1A6B16806DAD

Q27826351-730EC274-D369-4594-A2A1-3421E0A05A56

Q27826351-81B1F2D0-34E1-4755-A1B8-876BD1B97E9B

Q27826351-86F10FDB-9300-4C15-8EAD-BCB5ECEDCB1E

Q27826351-DCA8ED29-3BC8-45E6-B996-28D2C14A9A56

P932

Q27826351-503D6CD0-F9D7-4B1D-807C-02B2D05D7204

P3181

P356

JOURNAL.PPAT.1005763

P1433

P1476

Open Source Drug Discovery wit ...... Neglected Diseases and Beyond

@en

P2093

Abhai K Tripathi

http://www.w3.org/2001/XMLSchema#string

Ainhoa Alzualde

http://www.w3.org/2001/XMLSchema#string

Aintzane Alday

http://www.w3.org/2001/XMLSchema#string

Aishah Alsibaee

http://www.w3.org/2001/XMLSchema#string

Alvine N Mfopa

http://www.w3.org/2001/XMLSchema#string

Amornrat Naranuntarat Jensen

http://www.w3.org/2001/XMLSchema#string

Andreas Spitzmüller

http://www.w3.org/2001/XMLSchema#string

Andrew F Wilks

http://www.w3.org/2001/XMLSchema#string

Andrew Hemphill

http://www.w3.org/2001/XMLSchema#string

Ani Galstian

http://www.w3.org/2001/XMLSchema#string

P2860

Thousands of chemical starting points for antimalarial lead identification

Spiroindolones, a potent compound class for the treatment of malaria

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials

Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites

Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5

Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials

Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine

How many drug targets are there?

P304

e1005763

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2985726

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PPAT.1005763

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer Keiser

Sally-Ann Poulsen

Wesley C Van Voorhis

George Papadatos

David A. Fidock

Gregory J. Crowther

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27467575

http://www.w3.org/2001/XMLSchema#string

P921

open-source software

open-source drug discovery

P932

4965013

http://www.w3.org/2001/XMLSchema#string